Our researchers and posters @ESPGHAN 2023
Last week, we proudly presented our two poster on real-world evidence studies at ESPGHAN 2023 in Vienna. These two studies show that infants consuming Kabrita have significantly fewer GI symptoms and skin symptoms than infants not consuming goat milk formula, based on a lower CoMiSS® score. These results indicate that infants can benefit from Kabrita in managing GI symptoms and skin symptoms.
Want to have closer look at our posters? Please click here
Goat milk-based infant formula and the prevalence of GI symptoms in infants: A real world evidence study from Brazil, Mexico, Russia and The Netherlands
Conclusion: children fed GMF showed a low prevalence of GI symptoms. Moreover, GMF-consumers showed a lower CoMiSS® compared to non-GMF-consumers and parents indicated a lower prevalence of GI symptoms in their child after introduction of GMF than before introduction. These results support a potential benefit of GMF in managing GI symptoms in children. Further research is required to confirm these results.
Less gastrointestinal symptoms in infants consuming goat milk-based infant formula: a-real-world-evidence study
Conclusion: infants consuming GMF or CMF show a normal prevalence of GI symptoms, normal eating behaviour and their parents’ experience a good quality of life. However, infants consuming GMF have significantly less GI symptoms than infants consuming CMF based on lower CoMiSS®. These results might indicate that infants can benefit from GMF in managing GI symptoms (especially regurgitation) and skin symptoms.
Related publications
Interested to learn more about our brands and our company? Check out our other publications!
